The NVX-CoV2373 COVID-19 vaccine offers significant protection against symptomatic infections, but its effectiveness against SARS-CoV-2 declines within four months, according to a study in JAMA Network Open using Italian data. However, its protection against symptomatic COVID-19 seems to remain stable during this period.
SEC fines former Merck exec over insider trading allegations
The Securities and Exchange Commission said a former Merck executive agreed to pay $82,000 after alleging he purchased shares of a company right before it was acquired by the drugmaker. Nirdosh